Cathelijne Fokkema
4PUBLICATIONS
39CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Dec 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.Cathelijne Fokkema, Luca Bertamini, Madelon M E de Jong
|Oct 08, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero
|Feb 28, 2025
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.Charlotte L B M Korst, Sabrin Tahri, Carolien Duetz
|Feb 26, 2025
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma.Matteo Claudio Da Vià, Francesca Lazzaroni, Antonio Matera
Pageof 1
Frequent Collaborators
3 joint publications
Vincent H J van der Velden
3 joint publications
Pieter Sonneveld
2 joint publications
Luca Bertamini
2 joint publications
Mathijs Arnoud Sanders
2 joint publications
Gregory van Beek
2 joint publications
Madelon M E de Jong
2 joint publications
Sabrin Tahri
1 joint publications
Akihiro Maeda
1 joint publications
Vanessa Desantis
1 joint publications
Giuseppe M Peretti
